Wenqing Jiang

Wenqing Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XYXiaoping Yang
Xiaoping Yang
DWDongmei Wang
Dongmei Wang
CLChunxiao Li
Chunxiao Li
YZYujing Zhang
Yujing Zhang
JYJinghua Yang
Jinghua Yang
CWChao Wang
Chao Wang
Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality that leverages the endogenous ubiquitin-proteasome system (UPS) to

1 September 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XYXiaoping Yang
Xiaoping Yang
HNHongxin Niu
Hongxin Niu
WJWen Jiang
Wen Jiang
WYWanpeng Yu
Wanpeng Yu
WJWenqing Jiang
Wenqing Jiang
Chinese herbal medicines (CHMs) is the crystallization of wisdom accumulated by the Chinese nation over thousands of years. With the development and advancement of technology, extensive research has been conducted on the pharmacological activities of active components in CHMs. Natural constituents from medicinal plants exhibit rich scaffold diversity and structural complexity, playing crucial roles in the pharmacological effects of CHMs. However, many CHMs components have been found to suffer from poor water solubility, low stability, and limited bioavailability, which significantly restrict their clinical applications. In recent years, nanomedicine has been leveraging the power of nanotechnology to fully exploit its distinctive advantages. In the field of CHMs, the introduction of nanonization technology has enhanced the therapeutic efficacy of CHMs formulations. Especially the use of nano-modified CHMs solely derived from natural products has overcome several “bottlenecks” associated with chemical nanodelivery systems—such as insufficient drug loading, high production costs, potential systemic toxicity, and immunogenicity—emerging as an innovative and promising platform for disease treatment. Here, we review recent advancements in pharmaceutical nanotechnologies for CHMs in the treatment of pulmonary diseases and lung cancer. These nano-modified CHMs include nanoemulsions, self-assembled nanoparticles, nanocrystals, herbal-derived exosomes, and carbon dot-based nanozymes formulated from natural medicinal plants. They demonstrate unique advantages in enhancing the pharmacological effects of natural bioactive compounds and treating pulmonary disorders and lung cancer. This provides novel insights into the development of nano-modified CHMs in the treatment of pulmonary disease and lung cancer.

11 November 2022 in Frontiers in Psychiatry
Verified
Journal Article
Open access
WXWen Xu
Wen Xu
QDQiang Ding
Qiang Ding
Ying ZhaoYing Zhao
Ying Zhao
WJWenqing Jiang
Wenqing Jiang
JHJingjing Han
Jingjing Han
JSJinhua Sun
Jinhua Sun
Objective: To investigate the adaptability of Comprehensive Behavioral Intervention for Tics (CBIT) for a Chinese population, and evaluate the efficacy of combined CBIT and pharmacotherapy (CBIT + PT) compared to CBIT or pharmacotherapy (PT) alone for reducing tics and for improving the quality of life (QoL) in a sample of Chinese children with chronic tic disorders (CTD) and Tourette syndrome (TS).Materials and methods: In this 10-week randomized controlled pilot trial, 37 outpatients aged between 6 and 16 years affected by TS and CTD were randomly assigned to receive CBIT (n = 22) or PT alone (n = 15). Considering the feasibility, the patients allocated to the CBIT treatment group could further choose whether to simultaneously take medicine voluntarily, resulting in a CBIT alone group (n = 12) and a CBIT + PT group (n = 10).Results: At baseline, no significant difference was found between the three groups in the demographic and clinical characteristics (p > 0.05). All three groups showed a significant reduction in tic severity after treatment assessed by the Yale Global Tic Severity Scale (YGTSS) severity score [F(2,33) = 35.05, p < 0.001, ηp2 = 0.51], the score of the Clinical Global Impression scale for Improvement (CGI-I) [F(1,34) = 13.87, p = 0.001, ηp2 = 0.29], and YGTSS impairment score [F(2,33) = 31.71, p < 0.001, ηp2 = 0.48]. Significant interactions were found between the time-point and group in emotional functioning [F(2,29) = 4.39, p = 0.02, ηp2 = 0.23], psychosocial functioning [F(2,29) = 5.93, p = 0.007, ηp2 = 0.29], and total QoL score [F(1,34) = 3.72, p = 0.04, ηp2 = 0.20] of Pediatric Quality of Life Inventory (PedsQL 4.0) for children suggesting a significantly larger improvement in emotional functioning, psychosocial functioning, and total QoL score of the life quality in the CBIT group for children self-report. PedsQL for proxy report only showed a significant main effect of time-point in physical functioning [F(1,33) = 8.35, p = 0.01, ηp2 = 0.2], emotional functioning [F(1,33) = 10.75, p = 0.002, ηp2 = 0.25], psychosocial functioning [F(1,34) = 11.38, p = 0.002, ηp2 = 0.26], and total Qol score [F(1,34) = 13.21, p = 0.001, ηp2 = 0.29].Conclusion: CBIT is probably effective in reducing tic severity in Chinese children with tic disorders. CBIT + PT may not be superior to CBIT alone in reducing tic severity and improving quality of life. CBIT alone showed advantages in improving quality of life over CBIT + PT and PT alone. CBIT might be an appropriate treatment option for patients with tic disorder in Chinese mainland.

1 January 2022 in Turkish Neurosurgery
Verified
Journal Article
Open access
QBQing Bao
Qing Bao
XYXuesong Yuan
Xuesong Yuan
XBXiaoxing Bian
Xiaoxing Bian
WWWenfeng Wei
Wenfeng Wei
PJPeng Jin
Peng Jin
WJWenqing Jiang
Wenqing Jiang
The aim of this study was to measure the expression of translocator protein (TSPO) in brain tissue following traumatic brain injury (TBI) and determine whether TSPO can predict patient outcomes. TBI patients requiring removal of intracranial hematoma were recruited from Wujin Hospital Affiliated with Jiangsu University between January 2018 and March 2021. TBI patients were divided into unfavorable and favorable groups according to the Glasgow Outcome Scale (GOS) score. The level of TSPO in brain samples was analyzed by Western blot and immunocytochemistry. The expression of TSPO in the unfavorable group was higher than that in the favorable group. Double immunofluorescence staining showed that the percentages of TSPO positive cells among IBA1 positive and GFAP positive cells were 45.2± 3.1% and 3.5±0.6% respectively. After adjusting for age, sex, Computed tomography (CT), intracranial pressure (ICP) and Glasgow coma scale (GCS), we found that each 1-unit increase in TSPO was associated with a 40% higher occurrence of an unfavorable outcome (OR =1.4, 95% CI 0.4-5.6). The area under the receiver operating characteristic curve (AUC), specificity, and sensitivity of TSPO were 0.87, 76.7%, 88.2% respectively. Our study demonstrated that higher TSPO expression was associated with a higher occurrence of unfavorable outcomes.

23 May 2025 in Medicine
Verified
Journal Article
Open access
QJQian Mmed Jiang
Qian Mmed Jiang
YLYongji Mmed Liu
Yongji Mmed Liu
XCXiuhui Mmed Chai
Xiuhui Mmed Chai
XYXiaoping Yang
Xiaoping Yang
BYBin Yin
Bin Yin
WJWenqing Jiang
Wenqing Jiang
Rationale: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (MDA5-DM) is an autoimmune disease, characterized by a particular skin ulcer and rapidly progressive interstitial lung disease (RP-ILD). This case highlights diagnostic challenges of this disease and underscores the importance of early recognition and timely intervention. Patient concerns: A 59-year-old woman presented to the hospital with systemic myalgia, fatigue, and anorexia. Following admission she developed recurrent fever. Computed tomography of the chest and bronchoalveolar lavage fluid analysis revealed severe pulmonary infections. Despite 2 weeks of antimicrobial therapy yielding radiographic improvement, her dermatomyositis symptoms worsened. Diagnoses: Immune profiling and myositis-specific antibody testing confirmed the diagnosis of MDA5-DM-ILD. Interventions: The following treatment included methylprednisolone combined with immunosuppressants (tofacitinib, tacrolimus, tocilizumab, mycophenolate mofetil). Subsequent computed tomography imaging demonstrated cavity lesions and micronodules, with lung biopsy confirming fungal and viral coinfections. Therapy was adjusted to sustained methylprednisolone (22 mg/d), tacrolimus (0.5 g/d), targeted antimicrobials (ganciclovir, voriconazole) and prophylactic use of sulfamethoxazole complex. Outcomes: At discharge, the patient achieved clinical stability with resolved fever, normalized oxygen saturation and improved myalgia, though mild epigastric discomfort persisted. Lessons: MDA5-DM-ILD poses challenges for clinicians due to its diagnostic difficulty, rapid progression and secondary infection risks. Early immunosuppression combined with infection prevention is the key to a successful treatment of this disease.

24 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XYXiaoping Yang
Xiaoping Yang
YLYongji Liu
Yongji Liu
WJWen Jiang
Wen Jiang
XLXiaochun Liu
Xiaochun Liu
XZXiaonan Zhang
Xiaonan Zhang
WJWenqing Jiang
Wenqing Jiang
This study investigates the mechanisms of Osimertinib resistance in lung adenocarcinoma (LUAD) by identifying prognostic genes associated with SUMOylation. We performed differential expression analysis to identify differentially expressed genes (DEGs) in LUAD samples, Osimertinib-tolerant cell samples and SUMOylation-related genes (SRGs). Utilizing Cox regression and LASSO regression, we developed a prognostic model that highlighted five key prognostic genes—BIRC5, AURKA, BLM, NR3C2, and NDC1. These genes were significantly associated with LUAD progression, revealing their predominant expression in epithelial cells, which play a vital role in tumor development. Furthermore, we explored the biological functions and signaling pathways linked to these prognostic genes, discovering that their expression levels and corresponding risk scores could serve as indicators of CD4 T cell and memory B cell activation. The enriched signaling pathways in LUAD were regulated by ubiquitin-related small modifiers, highlighting the complex interplay between SUMOylation and tumor biology. Our findings suggest the important role of SUMOylation-regulated genes in LUAD progression and Osimertinib resistance, suggesting their potential as valuable biomarkers for prognosis and therapeutic targets to enhance treatment strategies for patients with EGFR-mutant lung adenocarcinoma.